NCT06361940View on ClinicalTrials.gov

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Breast Cancer

Interventions

DRUG

Aromatase inhibitors or tamoxifen

Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.

Trial Locations (1)

53226

RECRUITING

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors

lead

Medical College of Wisconsin

OTHER